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Objectives: The outcomes reported in trials in coronavirus disease 
2019 are extremely heterogeneous and of uncertain patient rele-
vance, limiting their applicability for clinical decision-making. The 
aim of this workshop was to establish a core outcomes set for trials 
in people with suspected or confirmed coronavirus disease 2019.
Design: Four international online multistakeholder consensus 
workshops were convened to discuss proposed core outcomes 
for trials in people with suspected or confirmed coronavirus di-
sease 2019, informed by a survey involving 9,289 respondents 
from 111 countries. The transcripts were analyzed thematically. 
The workshop recommendations were used to finalize the core 
outcomes set.
Setting: International.
Subjects: Adults 18 years old and over with confirmed or sus-
pected coronavirus disease 2019, their family members, mem-
bers of the general public and health professionals (including 
clinicians, policy makers, regulators, funders, researchers). 
Interventions: None.
Measurements: None.
Main Results: Six themes were identified. “Responding to the crit-
ical and acute health crisis” reflected the immediate focus on saving 
lives and preventing life-threatening complications that underpinned 
the high prioritization of mortality, respiratory failure, and multiple 
organ failure. “Capturing different settings of care” highlighted the 
need to minimize the burden on hospitals and to acknowledge out-
comes in community settings. “Encompassing the full trajectory and 
severity of disease” was addressing longer term impacts and the 
full spectrum of illness (e.g. shortness of breath and recovery). “Dis-
tinguishing overlap, correlation and collinearity” meant recognizing 
that symptoms such as shortness of breath had distinct value and 
minimizing overlap (e.g. lung function and pneumonia were on the 
continuum toward respiratory failure). “Recognizing adverse events” 
refers to the potential harms of new and evolving interventions. 
“Being cognizant of family and psychosocial wellbeing” reflected 
the pervasive impacts of coronavirus disease 2019.
Conclusions: Mortality, respiratory failure, multiple organ failure, 
shortness of breath, and recovery are critically important out-
comes to be consistently reported in coronavirus disease 2019 
trials. (Crit Care Med 2020; XX:00–00)
Key Words: clinical trial; coronavirus; critical care; infection; 
patients; sepsis
Coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO) on March 11, 2020. Patients with COVID-19 
have an increased risk of mortality and multiple organ failure 
and debilitating symptoms including dyspnea, chest pain, and 
fatigue (1–6). The pandemic has imposed an unprecedented 
burden on healthcare systems worldwide, with demand for 
critical care exceeding capacity in some countries (7–10). As 
yet, there are no treatments proven to be effective (11).
In response to this crisis, clinical trials in COVID-19 have 
been initiated very rapidly. As of July 6, 2020, 4,098 trials were 
registered in the WHO International Clinical Trials Registry 
(12). The use of evidence from these trials to inform clinical 
decision-making is problematic, in part because the heter-
ogeneity of outcomes reported across trials precludes robust 
comparisons across trials. Also, the outcomes of relevance to 
patients and clinicians may not always be reported. In a WHO 
review of outcomes used in 84 registered trials in COVID-19, 
six trials (7%) included mortality and 25 (30%) included lung 
injury indicated by oxygen saturation, respiratory failure, chest 
imaging, and oxygenation index (13).
The problems with heterogenous reporting of outcomes in 
trials are well known. Core outcome sets have been established 
to ensure that critically important outcomes are consistently 
reported in all trials (14, 15). There have been three initiatives 
to identify core outcomes for trials in COVID-19, all of which 
have established mortality and respiratory failure as core out-
comes (13, 16–18). Mortality and respiratory failure in hos-
pitalized patients were identified by all three initiatives (19). 
However, the prior initiatives involved a limited number of 
stakeholders (~70 to 135) and countries (1–25) (13, 16, 18, 19). 
Only one initiative involved patients and the public, who were 
all from China. This is of concern as patient-important out-
comes are often omitted from trials (20).
To ensure broad inclusion of stakeholders globally, in-
cluding patients and the general public, the COVID-19-Core 
Outcomes Set (COS) project was launched in March 2020 to 
establish a core outcomes set for trials in people with con-
firmed or suspected COVID-19 (21) across the full spectrum 
of disease and in all settings. The process was based on the 
Core Outcome Measures in Effectiveness Trials (COMET) 
framework (14) and involved a systematic review of out-
comes reported in published and registered trials, an inter-
national online survey conducted in five languages involving 
9,289 respondents from 111 countries (22) and four consensus 
workshops. In this report, we summarize the workshop dis-
cussions on establishing the core outcomes set and present the 
final COVID-19-COS core outcomes set.
METHODS
Overview and Context
Four online COVID-19-COS consensus workshops were con-
vened from 14 to 15 of April 2020 using the video conferencing 
platform, Zoom, to discuss a proposed set of core outcomes 
that were identified from a prior international survey that in-
volved 9,289 respondents (people with suspected or confirmed 
COVID-19 and their family members [n = 776]), members 
of the general public (n = 3,631), and health profession-
als (n = 4,882) from 111 countries (22, 23). The survey was 
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conducted in five languages. At the workshop, we presented the 
top 10 rated outcomes identified by the survey respondents: 
mortality, respiratory failure, pneumonia, organ failure, lung 
function, lung scarring (fibrosis), sepsis/septic shock, short-
ness of breath, oxygen saturation, and hospitalization. These 
outcomes had a mean score greater than 7.5 (on a nine-point 
Likert scale, 7–9 being of critical importance), median greater 
than or equal to 8, with greater than 70% of respondents rat-
ing the outcome from 7 to 9 in each of the three stakeholder 
groups (patients/family members, public, and health profes-
sionals). The survey will be published separately.
Participants and Contributors
We invited people with suspected or confirmed COVID-19 18 
years old and over, family members, members of the general 
public, and health professionals (physicians with expertise in 
critical care medicine, pulmonary and respiratory disease, in-
fectious disease, emergency medicine, cardiology, nephrology, 
nurses, multidisciplinary clinicians, researchers, funders, and 
policy makers) through the Steering Committee and Inves-
tigators and social media, with invitations sent by e-mail. In 
total, 95 attendees (including 17 with suspected/confirmed 
COVID-19) from 21 countries (Australia, Austria, Belgium, 
Brazil, Canada, Chile, China [mainland China and Hong Kong 
SAR], France, Germany, Italy, Japan, Portugal, Republic of Ire-
land, Saudi Arabia, South Africa, South Korea, Spain, Switz-
erland, United States, United Kingdom) participated. The full 
list of workshop attendees and investigators is provided in the 
acknowledgments.
Workshop Program and Process
During each workshop, we presented the COVID-19-COS pro-
cess, results from the survey, and a proposed core outcomes set. 
The attendees were then allocated into two virtual breakout 
rooms, each including people with COVID-19, members of the 
general public, and health professionals. The facilitator asked 
participants to discuss the proposed core outcomes. For feasi-
bility of implementation, it was recommended that the core set 
should be comprised of three to five outcome domains, including 
at least one patient-reported outcome (14, 24). All 38 outcomes 
in the survey, including those added by survey respondents were 
shown to the participants. The five outcomes proposed for the 
core outcomes set presented at the workshop were as follows: 
mortality, respiratory failure, multiple organ failure, sepsis, and 
shortness of breath. Lung function, lung fibrosis, and pneu-
monia that were rated highly in the survey were not included in 
the proposed core outcomes set because of the overlap with res-
piratory failure and shortness of breath. All discussions were re-
corded and transcribed verbatim. The transcripts were imported 
into HyperResearch (ResearchWare Inc, version 3.0, Randolph, 
MA) for analysis. Using thematic analysis (25), author (A.T.) in-
ductively identified themes on establishing core outcomes for 
trials in people with confirmed or suspected COVID-19. All 
attendees and investigators received the draft report, which in-
cluded the final recommended COVID-19-COS core outcomes 
set (Fig. 1), and were invited to provide feedback by e-mail.
RESULTS
The themes are described in the following section with selected 
quotations from the workshops provided in Table 1. Box 1 
outlines the recommendations from the consensus workshops.
Responding to the Critical and Acute Health Crisis
Focus on Saving Lives. Mortality was consistently identified 
as the most important outcome, which reflected the pressing 
Figure 1. COVID-19-Core Outcomes Set (COS).
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TABLE 1. Selected Quotations
Themes Quotations
Responding to the critical and acute health crisis
 Focus on saving 
lives
Right now the focus is keeping patients alive.
There is one outcome that is far and away driving action and concern about this, and that is mortality. 
Everything else is secondary to the risk of death, for a self-limited acute disease where there is a 
substantial mortality. That is the major thing that we are trying to avert here, from the point of view of 
interventions. We are looking for interventions that will stop patients from dying. I would place mortality 
as out and away as a separate order of magnitude of importance.
Mortality of course, because we see people dying, even young people without any comorbidity, they can 
end up on the ventilator and eventually die later on. We have several cases of young people, a very un-
fortunate one, a young girl of 12 yr who died in the ambulance to the hospital.
 Preventing life-
threatening 
complications
Right now the focus is keeping patients out of hospital, keeping them organ failure free out of the ICU 
and discharge home.
Focus on the most severe end of the disease, these are problems that are going to, particularly mortality, 
multiple organ failure, sepsis, are clearly issues really for people who end up either in intensive care or 
who would go to intensive care were that to be an appropriate place for them to go.
Multiple organ failure and the sepsis is a big one because I am one of the immunocompromised, I am in 
that high-risk category of COVID.
 Respiratory failure, multiple organ failure, sepsis are on the pathway to death unfortunately, and their sig-
nificance is that that is what they lead to.
Multiple organ failure is also important in my head because I do not know if he was going to then go into 
AKI because of COVID.
It is very important respiratory failure because that is what everybody is so much afraid about to end up at 
the ICU and on the ventilator.
It should be “severe” respiratory failure.
Capturing different settings of care
 Minimizing burden 
on hospitals
Respiratory failure this position of the patients whether they are going to be cared for on the general 
ward, or whether they need admission into intensive care.
There is the need to have outcomes that capture the hospital resources. Outcomes such as admission to 
hospital, admission to ICU, need for a ventilator to capture the different terms and labels of resources 
that we have in decent healthcare systems.
We are trying to protect the healthcare system.
The most relevant thing here is actually the need that patients will require mechanical ventilation, which 
can be actually one of the important core outcomes in patients. We have two separate basically two 
groups of patients with COVID. The patients who are treated in a normal ward. They are critical to cer-
tain extent until they need an ICU admission, and once the patients are admitted to the ICU, you will 
have a different situation actually with other outcomes of interests.
 Recognizing 
events occurring 
in community 
contexts
We have 258 cases who died and 134 died outside of the hospital, mostly in aged care facilities. We 
were facing a bottleneck with the ability to admit patients and ventilate patients in ICU. A lot of people 
in aged care facility who were severely ill were not even admitted in hospital, because we knew that if 
they were admitted they would have required ICU which we could not offer to them.
People who have suspected COVID-19 have the milder conditions would not necessarily end up at hospitals.
I was in the hospital briefly, but not hospitalized per se. Multiple organ failure and sepsis were not an issue 
for me, but the shortness of breath, the breathing issues, I had a significant headache that I cannot 
begin to describe the severity of it.
How much of these outcomes will be used in community studies as opposed to in hospital studies? My 
understanding is that COVID, certainly in the United Kingdom is absolutely prevalent in the community 
and we are not being tested so we do not know.
I was at home for the duration of my illness. Luckily, I did not have it to a point where I needed to go to 
hospital or anything. My main thing was that I was so exhausted I could not move or do anything.
(Continued )
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TABLE 1. (Continued). Selected Quotations
Themes Quotations
 Ensuring relevance 
and feasibility 
in low resource 
regions
The options of ventilation and so on are restrictive. It is very relevant to realize that round about 87% of 
the world’s population actually live in low middle-income class countries. It literally has been a day and 
night job in our setting and for many of our friends elsewhere, and in fact on the continent of Africa… 
some of whom may not be able to in any context even offer ventilation—it is just not feasible.
We are several weeks behind most of you, so launching the planning phases but we are seeing increas-
ing numbers of patients and where ICU facilities do exist, and we are getting away in many instances 
the use of polymasks and proning a patient, without necessarily invasively ventilating them and patients 
who got saturation’s of 70% and 80%, where ordinarily in any other context these patients would have 
been invasively ventilated.
The other thing that is really important is that we make sure that whatever definition we use is applic-
able across as wide a range of context as possible. So ECMO and something is very important in the 
developed world and so forth, but there are countries where ECMO is simply not available. In fact there 
are countries where even mechanical ventilation is not available. So we must make sure I think that this 
is as applicable across contexts as we can manage whilst not collapsing things of saying advanced re-
spiratory support is all the same, but also to try and capture from as many contexts as possible so that 
trials do take place in less well resourced areas can also take part in the core outcome set.
I am speaking on behalf of the low- and middle-income countries. We have seen a lot of patients with 
multiple organ failure because these patients arrived late in the hospital because sometimes they are 
stuck in the other parts of the national healthcare system. Multiple organ failure will be an important 
issue in this scenario.
Encompassing the full trajectory and severity of disease
 Addressing 
prognostic 
uncertainty 
and long-term 
concerns
The most important thing to me would not be if I died with COVID, it is just if I got it and was worse and it 
destroyed say half my lung function or to quality of life.
It is about ability to function afterwards. I have no comorbidities to my knowledge, but what is worrying me 
now is post viral fatigue and recovery, because it is been a very long time since I’ve spent 2 wk in bed, 
and I am showing no signs of being strong enough to even function in the house, never mind go back 
to work. What is concerning me about a long-term recovery is that kind of post viral thing, and then also 
are there lung injuries for people that do not even have comorbidities? Am I at risk of suffering some 
term loss of some lung function?
I am at day 26 now of having the disease, and I still have a fever, and I still have a really high heart rate, 
and I still have shortness of breath and chest pain and a cough. I am grateful that I am not in hospital 
with more dire symptoms. I am a musician and I use my lungs for a lot of things. The long-term effects 
of the disease would be something good to look at.
In terms of fatigue, I am a very active person and I cannot stand for more than 10 min anymore, and that 
is a really weird feeling in my 20s.
I am really scared when they do tell me that I can go and get an x-ray, what my lungs are going to show 
because I have never had that kind of chest pain and shortness of breath before.
I had side respiratory failure and I would like to make a pitch for some long-term consequence of COVID-
19 infection being included in the core outcome, such as pulmonary fibrosis. Because you could 
imagine a kind of discreet choice experiment, where a clinician or a patient or a health provider has 
to decide, “Do we ventilate harder to get the patient off the ventilator sooner, but risk more pulmonary 
fibrosis long-term?”
 Applicable to mild 
and moderate 
disease
I treated about 30 patients with COVID-19, some mild patient, some mild disease. They were hospitalized 
on a standard floor, so they were treated with first some oxygen by the nasal prongs.
There will be a period of recovery. This week I can have a shower and go downstairs and have breakfast 
and I am not short of breath, whereas last week I could not do that. So that is an indicator of some 
measure of recovery.
Shortness of breath can be a good outcome parameter in the sub pool of patients who are admitted to 
normal ward, not patients in ICU.
Fatigue, shortness of breath are very important from patient perspective especially in patients who have 
milder form of disease.
 Absence of disease [recovery], which surely is one of the outcomes that one is trying to accomplish when 
one is conducting a trial is to cure people and to get rid of the disease.
(Continued )
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Distinguishing overlap, correlation, and collinearity
 Symptoms having 
distinct value
Shortness of breath was one that was quite debilitating for me, in terms of trying to do some normal 
things like washing, like cloth washing or tidying the flat, I had get very short of breath. It was the short-
ness of breath and the fatigue that lasted the longest, and it was at that stage when I did not have the 
fever or anything else. How long until these symptoms go so I can get back to a level of normality in 
life, and go back to work, do gentle exercise?
The issue with shortness of breath is, it is not very specific but that may be a good thing, because it is 
more sensitive in that regard.
Shortness of breath is strongly related to ICU-acquired weakness.
We should be including shortness of breath to capture that patient experience.
I consider myself somebody who has got a moderate case. I have been dealing with this almost 4 wk now 
and I am still having shortness of breath and other symptoms. It is troublesome not to be able to breathe.
Even though I do not have the virus in my body, I am still having shortness of breath, chest tightness, and I 
am still coughing as well.
Shortness of breath maybe important in self isolated patients at home, usually a chest radiograph cannot 
detect the pneumonia in COVID-19. Some of these patients who have shortness of breath, can, pro-
gress quickly to the respiratory failure, so the shortness of breath maybe can be the only sign of the 
respiratory failure or pneumonia.
There are ICU data showing that shortness of breath, even a patient on a ventilator has some prognostic 
significance. So shortness of breath seems to be different from respiratory failure and [the patient’s] 
comments about her father having respiratory failure but not being short of breath, quite pertinent. I 
think it matters to the person about how they feel. And so I would favor including shortness of breath.
 Clarifying causal 
pathways
There is a major overlap between multi organ failure and sepsis, particularly with the definition change in 
sepsis, where organ failure is vital to that. Those are really the same thing because this is drive by an 
infection so therefore by definition any multi organ failure arising from COVID is sepsis.
If we are going to combine them to delete the sepsis terminology. Sepsis is a very vague condition.
Multiple organ failure is a bit tenuous but it is important, we have seen a lot of kidney damage, a lot of AKI, a 
lot of need for dialysis and it seems to be effecting outcomes or how well or how poorly they are going to do.
I have been rounding for almost 4 wk now in a row, is very variable if the patients are going to go into 
multiple organ failure or not. The one that I have in the unit, obviously they have more chance of having 
multiple organ failure.
Multiple organ failure and sepsis was somewhere on the causal pathway between the respiratory failure 
and mortality.
Most of the cases that we saw so far in our institution, they died not only from the respiratory failure, they 
died actually from non-respiratory organ failure. So non-respiratory organ failure can also be an im-
portant outcome parameter in these patients, mostly coagulation failure.
Recognizing adverse events
There is a lot of studies that are being started that are evaluating hydroxychloroquine for example, which 
has adverse events. So especially the population of patients who are not as severe, so instituting this 
treatment can be problematic and can institute adverse events.
Adverse events are often intervention specific and so they are not going to have a common domain across 
all different drug classes or other intervention foci in an area here where there does not seem to be any 
compelling cases or effective interventions at present, that just adds to the uncertainty.
A topic that is of relevance is also the harms, the side effects. We are potentially going to be trialling a 
lot of novel interventions. The question is, what is the trade-off between the potential benefits, the 
respiratory failure, whatever, and those harms which probably we are going to have to accept to obtain 
certain benefits.
We should be aware of the variation in approach to treatment around the world and the way that that is 
evolving quite rapidly. Outcomes that are more based on physiologic state rather than the initiation of a 
particular therapeutic intervention may be a better approach.
TABLE 1. (Continued). Selected Quotations
Themes Quotations
(Continued )
Clinical Investigation
Critical Care Medicine www.ccmjournal.org 7
primary goal of “keeping patients alive” and managing the 
“crisis” of the global pandemic. Death was identified as the 
worst outcome and was “far and away driving action and con-
cern about [COVID-19], the major thing we’re trying to avert 
from the point of view of interventions.”
Preventing Life-Threatening Complications. The high 
priority placed on mortality, respiratory failure, and multiple 
organ failure resonated with the urgent need to manage severe 
and critical cases of COVID-19. It was suggested that respi-
ratory failure should be defined as “‘severe’ respiratory failure 
because that’s what everybody is so much afraid of, to end up at 
the ICU and on the ventilator.” Some patients were concerned 
that many who were placed on a ventilator did not recover. 
These severe outcomes were particularly feared among vulner-
able populations—“multiorgan failure is a big one because I’m 
one of the immunocompromised; I’m in that high-risk cate-
gory of COVID having severe reactions.”
Capturing Different Settings of Care
Minimizing Burden on Hospitals. The need to “protect the 
healthcare system” supported the inclusion of outcomes rel-
evant to the hospital setting. Some countries encountered 
difficulties in mobilizing healthcare resources during the 
early phase of the pandemic. Respiratory failure was impor-
tant because it determined if patients would require admis-
sion to intensive care. Health professionals suggested that 
the use of hospital resources should be embedded in how 
the core outcomes were defined—“kidney failure could be 
defined as need for kidney replacement therapy. Respiratory 
failure could be defined based on what respiratory support 
you require.”
BOX 1. Summary of the Workshop 
Recommendations to Consider in 
Establishing Core Outcome Domains for  
Trials in People With Suspected or 
Confirmed Coronavirus Disease 2019
Core outcome domains for trials in people with 
suspected or confirmed coronavirus disease  
2019 should:
 Reflect the immediate goals of saving lives and minimizing 
the burden on the health system (i.e. mortality, 
respiratory failure, multiple organ failure).
 Be applicable to care in a range of settings including 
hospital and community.
 Be relevant and feasible to use in low-resource settings.
 Inform decisions to manage both acute and long-term 
outcomes.
 Capture long-term prognostic concerns (e.g. shortness of 
breath).
 Include long-term functional outcomes that reflect the full 
disease trajectory including long-term outcomes (e.g. 
recovery).
 Consider applicability to people with severe and mild-to-
moderate COVID-19 (e.g. shortness of breath).
 Include prevalent and debilitating symptoms (i.e. shortness 
of breath) that are meaningful and critically important to 
patients and as a prognostic indicator.
 Include outcome domains that are adequately distinct (i.e. 
exclude sepsis from the core outcome set as multiple 
organ failure arising from COVID-19 infection is sepsis; 
lung health captures respiratory failure, lung function, 
lung scarring, pneumonia).
COVID-19 = coronavirus disease 2019.
Being cognizant of family and psychosocial wellbeing
The impact on family is quite huge to have those social issues to be looked at as well, considering when 
we are talking about people isolated in hospitals and do not have any contact with their family and 
how difficult that is and how stressful that is and could actually equate to you actually being sicker 
and deteriorating a lot quickly into depression and anxiety. We have seen people over on social media 
where they have had to stand outside and speak to their loved one on a walkie talkie to say goodbye 
because they are dying.
It is still depression to me or psychologic issues associated with the disease is still a very big thing, both 
for the family member. I was actually out of hospital before my father was, and I gave it to my father. I 
did not fall into depression, but I can actually see how people will have a lot of anxiety about passing it 
to their family members and also that they may go into depression.
Are we picking up anything on psychologic wellbeing or worry, anxiety, sense of control.
And then the last thing specific to the safety net population is this idea or this outcome of vitality and 
financial stability. I had several patients that actually left against medical advice, so still requiring oxygen 
and hospitalization, but left because they thought they needed to go back to work and there was 
nothing our hospital could do to keep them there in the hospital or to let their employer know that they 
were infected, but they had to go back to work because they were day laborers and needed to make 
an income for their family.
I was worried about whether I had given it to anybody when I went to the doctors. I was just constantly 
worried and I do not feel like anybody’s talking about the anxiety side of what having coronavirus does.
AKI = acute kidney injury, COVID = coronavirus disease, ECMO = extracorporeal membrane oxygenation.
TABLE 1. (Continued). Selected Quotations
Themes Quotations
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Recognizing Events Occurring in Community Contexts. 
Many people with COVID-19 were managed at home or in the 
community (e.g. aged care facilities), thus including outcomes 
relevant outside of the hospital setting was warranted. Patients 
who were not hospitalized emphasized that severe symptoms, 
including shortness of breath, fatigue, and headache, as well 
as recovery, were important—“there might be a distinction 
between people who are hospitalized and critically ill versus 
people who are managing it at home and recovering.” In some 
countries, people could not be admitted to ICU owing to lim-
ited hospital capacity; therefore, some participants advised 
that COVID-19 related mortality “needed to include out-of-
hospital deaths.”
Ensuring Relevance and Feasibility in Low-Resource Re-
gions. In some settings, particularly in low-income countries, 
mechanical ventilation, and extracorporeal membrane ox-
ygenation were not available—“we are getting away in many 
instances with proning a patient [positioning a patient flat on 
the stomach with the chest and head facing down], without 
necessarily invasively ventilating them; these are patients who 
have got saturations of 70 and 80%, where ordinarily in any 
other context those patients would have been invasively ven-
tilated.” Therefore, the definition and measure of respiratory 
failure also needs to also be applicable in low-income coun-
tries. Multiple organ failure was highly relevant in low- and 
middle-income countries—“we have seen a lot of patients with 
multiple organ failure because these patients arrived late in the 
hospital, because sometimes they are stuck in the other parts of 
the healthcare system [when they should be in ICU].”
Encompassing the Full Trajectory and Severity of 
Disease
Addressing Prognostic Uncertainty and Long-Term Concerns. 
The long-term impacts of COVID-19 are relevant. However, 
the specific outcomes of most importance were uncertain be-
cause of the lack of data on longer-term outcomes. Patients 
wanted to know about time to recovery—“what is worrying 
me now is post viral fatigue and recovery, because it’s been a 
very long time since I’ve spent two weeks in bed, and I’m show-
ing no signs of being strong enough to even function in the 
house, never mind go back to work. That’s what’s concerning 
me about a long-term recovery is that kind of post viral thing.” 
Health professionals suggested that recovery should be a core 
outcome—“I was surprised to not see recovery as a core out-
come in the first category.” Participants suggested considera-
tion of ongoing symptoms such as shortness of breath, fatigue, 
chest pain, and cough—“I’m in day 35 and I’m still struggling 
with shortness of breath.” Some patients were concerned about 
long-term impacts on lung health (e.g. lung function, lung 
scarring)—“I am really scared when they do tell me that I can 
go and get an x-ray, what my lungs are going to show because 
I’ve never had that kind of chest pain and shortness of breath 
before.” Long-term outcomes were relevant to make trade-offs 
in decision-making—“imagine a kind of discrete choice ex-
periment to decide, ‘do we ventilate harder to get the patient 
off the ventilator sooner, but risk more pulmonary fibrosis 
long-term?’ There’s a balance between the acute outcomes and 
the long-term consequences.”
Applicable to Mild and Moderate Disease . Shortness of 
breath, oxygen saturation, pneumonia, recovery, and fatigue 
were suggested to be important for people who did not have 
severe COVID-19—“if I were asymptomatic and in a trial I 
certainly would be interested in shortness of breath, but I’d 
also be interested in whether I needed to get admitted to the 
hospital.” To cover the spectrum of disease severity, partici-
pants recommended that outcomes related to postacute illness 
recovery be included—“absence of disease [recovery], which 
surely is one of the outcomes that one is trying to accomplish 
when one is conducting a trial is to cure people and to get rid 
of the disease.” Patients referred to recovery as being able to do 
usual activities—“There will be a period of recovery. This week 
I can have a shower and go downstairs and have breakfast and 
I’m not short of breath, whereas last week I couldn’t do that. So 
that’s an indicator of some measure of recovery.”
Distinguishing Overlap, Correlation, and Collinearity
Symptoms Having Distinct Value. Shortness of breath was a 
symptom that was “debilitating,” “lasted the longest,” and pre-
vented the ability to do usual daily tasks and thus captured an 
important aspect of the patient experience of COVID-19. It 
was recognized that shortness of breath could have value as 
a prognostic indicator because “a chest radiograph may not 
always detect pneumonia in COVID-19 and some of these 
patients who have shortness of breath can progress quickly 
to respiratory failure, so it may be the only sign of respiratory 
failure or pneumonia.” Health professionals advised that short-
ness of breath could be a symptom of COVID-19 and also re-
lated to ICU-acquired diaphragmatic weakness.
Clarifying Causal Pathways. Health professionals noted 
that sepsis was included in the definition of multiple organ 
failure—“sepsis is defined as organ failure due to infection. All 
the patients have infection, by definition.” Respiratory failure 
could “dominate the category of multiple organ failure.” How-
ever, some argued that multiple organ failure was justifiable 
as a core outcome because kidney damage or cardiovascular 
disease had been observed in people with COVID-19. Lung 
outcomes (respiratory failure, lung function, lung scarring, 
and pneumonia) were all of high priority, however were on a 
continuum inclusive of respiratory failure.
Recognizing Adverse Events
It was expected that “we are going to be trialling a lot of novel 
interventions” and participants urged awareness of the “varia-
tion in approach to treatment around the world and the way 
that that’s evolving quite rapidly.” However, without compel-
ling cases for effective treatments at present and with little 
commonality across different interventions (e.g. drug classes), 
potential intervention-specific adverse events may be excluded 
from the core outcomes set.
Clinical Investigation
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Being Cognizant of Family and Psychosocial 
Wellbeing
Due to the potentially severe nature of COVID-19 and re-
quirement for quarantine, emphasis was placed on the pro-
found impacts on the psychosocial wellbeing of patients and 
their families. Being in isolation was thought to exacerbate 
sickness, deterioration, depression, and anxiety for patients 
and their families—“we’ve seen people where they’ve had to 
stand outside and speak to their loved one on a walkie talkie to 
say goodbye because they’re dying.” Patients experienced guilt, 
fear, and depression related to infecting others.
The COVID-19-COS Core Outcomes Set
The recommendations (Box 1) arising from the workshop 
were used to finalize the core outcomes set based on review 
by the Steering Committee and investigators. Sepsis was 
moved from the initial core outcomes set into Tier 2 because 
of overlap with multiple organ failure. Lung function, lung 
fibrosis, and pneumonia remained in Tier 2 to avoid overlap 
with respiratory failure and shortness of breath. Shortness of 
breath was retained in the core outcomes set because it was the 
most important patient-reported outcome and was a symptom 
relevant across the spectrum of COVID-19 and across the full 
trajectory of an individual’s disease course. It was strongly and 
consistently recommended that a longer term outcome should 
be included. However, the top 10 ranked outcomes from the 
survey comprised only of acute and severe outcomes. Recovery 
(defined in the survey as how long it takes to recover, i.e., feel 
better, no longer having symptoms) was the highest rated 
long-term outcome and was moved from Tier 2 into the core 
outcomes set as in response. Six outcomes relating to symp-
toms and psychosocial and family impact (based on those that 
were highest ranked in the survey—chest pain, cough, depres-
sion, fatigue, impact on family, life participation) were moved 
from Tier 3 to Tier 2. The final COVID-19-COS core outcome 
domains are shown in Figure 1.
DISCUSSION
Overall, people with suspected or confirmed COVID-19, family 
members, the public, and health professionals agreed that 
mortality, respiratory failure, and multiple organ failure were 
the most critically important outcomes that should be core 
outcomes for all trials in COVID-19. These outcomes reflected 
the immediate goals of saving lives, preventing life-threatening 
complications, and protecting the healthcare system that were 
paramount in the current pandemic. Shortness of breath was 
identified as a persistent and debilitating symptom that im-
paired the ability to perform daily activities, was relevant to all 
levels of disease severity, and provided meaningful information 
about the patient experience of COVID-19. This symptom was 
also seen to have potential value as a diagnostic and prognostic 
indicator for lung health including pneumonia and respiratory 
failure or as a long-term outcome, for example, a sign of ICU-
acquired weakness. All stakeholders emphasized the impor-
tance of capturing the full severity and trajectory of disease in 
the core outcomes set, including long-term outcomes. There-
fore, recovery was included in the core outcomes set.
The workshop discussions and recommendations informed 
the selection of the core outcome domains to be reported in 
trials in people with confirmed or suspected COVID-19: mor-
tality, respiratory failure, multiple organ failure, shortness of 
breath, and recovery (Fig. 1, Panel 1).
Mortality, respiratory failure, multiple organ failure, and re-
covery have been identified as core outcomes for COVID-19 
by recent initiatives (13, 16, 17). The WHO core outcomes set 
for clinical research included three domains: survival (all-cause 
mortality at hospital discharge or 60 d), viral burden, and clin-
ical progression (including need for interventions for respiratory 
and multiple organ failure) (13). The COS-COVID core out-
comes set included viral load, hospitalization, oxygen saturation, 
respiratory failure (duration of mechanical ventilation), and 
mortality (16). Qiu et al (17) identified eight outcome domains, 
including recovery time and mortality, respiratory outcomes, 
and non-specified symptoms. The COVID-19-COS core out-
comes set includes the patient-reported outcome of shortness 
of breath, which has not been previously identified. Shortness 
of breath is a common and distressing symptom in people with 
lung disease and a potential predictor of mortality (26). A study 
in pulmonary rehabilitation in patients with chronic obstructive 
pulmonary disease identified shortness of breath as one of the 
most important outcomes for patients, caregivers, and health 
professionals (27). An international Delphi survey involving 
researchers, clinicians, patients/caregivers, and funders identi-
fied pulmonary symptoms as a core domain for survivors of 
acute respiratory failure after discharge from the hospital (28).
Further work is needed to identify valid core outcome 
measures for the core outcome domains that can be feasibly 
implemented in all trials in people with suspected or con-
firmed COVID-19. This will involve the review of established 
definitions and measures (including core measures) for mor-
tality, respiratory failure, multiple organ failure, and recovery 
and possible pilot and validation work to establish a patient-
reported outcome measure for shortness of breath that is psy-
chometrically robust and of minimal burden to implement.
CONCLUSIONS
With the rapidly growing body of evidence from clinical trials, 
urgent implementation of core outcomes in trials in COVID-
19 can help to improve the consistency of reporting outcomes 
that are critically important to patients, family members, the 
public, and health professionals. This can better inform deci-
sion-making in the context of this pandemic and strengthen 
the value of trials to inform the management of people with 
suspected and confirmed COVID-19 and hopefully improve 
patient outcomes.
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